Subcutaneous Revolution: Alteogen and BD Showcase Large-Volume Biologic Delivery Solution
As the development of high-dose biologic therapies accelerates across the biopharmaceutical industry, innovative drug-delivery systems designed to...
Search results for "subcutaneous injection"
Alteogen Secures U.S. Patent Registration for Keytruda SC Formulation
Alteogen announced on the 12th that it has secured registration with the United States Patent and Trademark Office for a formulation patent related...
Pediatric Crohn’s: Switching Biologics Yields Similar Remission Rates Despite Lower Blood Drug Levels
Pediatric and adolescent Crohn’s disease patients who switch to infliximab after losing responsiveness to adalimumab...
Hanmi Completes Key Phase 2 Dosing for Once-Weekly Rare Disease Drug Efpeglucagon
During normal digestion, dietary carbohydrates convert into glucose that circulates in the blood.
Zymfentra U.S. Sales Surge 176% as Celltrion’s Remsima Franchise Eyes 1 Trillion Won Annual Revenue
Biopharmaceutical company Celltrion announced on Aug. 27 that combined first-half sales of its subcutaneous infliximab...
JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug Bofanglutide
JW Pharmaceutical announced on Aug. 18 that it has submitted an Investigational New Drug application to South Korea’s...
VOYXACT Preserves Kidney Function for Two Years in Phase 3 IgA Nephropathy Trial
Otsuka Pharmaceutical’s VOYXACT (active ingredient: sibeprenlimab) demonstrated long-term kidney protection by...
Alteogen Signs $365 Million Licensing Deal for Subcutaneous Drug Delivery Platform ALT-B4
Biotechnology firm Alteogen has signed an exclusive technology-transfer agreement worth up to $365 million...
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven
Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.
Novo Nordisk Secures EU Green Light for Oral Wegovy, Outpacing Eli Lilly in the Pill Market
The glucagon-like peptide-1 (GLP-1) obesity treatment market, long dominated by subcutaneous injections, is rapidly...